Pientzehuang obtains approval for new fertility drug trial

Zhangzhou Pientzehuang Pharmaceutical (SSE:600436) announced it has received a "Notice of Approval for Drug Clinical Trial" from the National Medical Products Administration for its new drug, Yang Chao Granules. The drug, classified as a traditional Chinese medicine (TCM) 1.1, aims to treat kidney deficiency-related decline in ovarian reserve function. Derived from a long-standing formula, Yang Chao Granules have shown promising results in previous clinical applications.